ABSTRACT
Dr. Reddy's began by supplying active pharmaceutical ingredients and intermediates to other pharmaceutical companies for formulating their drugs. He was also involved in the discovery of new drug molecules in a few specific clinical areas: cancer, metabolic disorders and cardiovascular. The dominant treatment paradigm for heart disease was to treat Cardiovascular disease risk factors individually and manage each with great precision—prescribing medications on an individual basis. For patients who had already experienced a heart attack or stroke, the polypill could help prevent recurrence. The Red Heart Pill (RHP) had to be investigated for potential impurities and added toxicity, caused by the simultaneous release of its active ingredients into the bloodstream. R. K. Singh, another associate director in the Indian generics business, felt that selling RHP to the rural poor would need a different approach. Rural markets were projected to grow rapidly because of rising economic prosperity.
